THCB
Tetrahydrocannabutol · THCB · Discovered 2019
Explore THCB (Tetrahydrocannabutol), the butyl-chain cannabinoid discovered in 2019 with enhanced CB1 binding affinity. Learn about its potency, research findings, and relationship to THC and THCP.
Psychoactive
Yes
Discovered
2019
Effects
4 documented
Benefits
2 studied
Overview
Tetrahydrocannabutol (THCB) is a naturally occurring cannabinoid identified in 2019 by the Italian research team led by Dr. Cinzia Citti — the same group that discovered THCP and CBDP. THCB is a THC homolog featuring a four-carbon (butyl) alkyl side chain, placing it between THCV (three-carbon propyl chain) and standard THC (five-carbon pentyl chain) in terms of side chain length. This intermediate chain length gives THCB a unique pharmacological profile distinct from both THC and THCV.
In the initial 2019 characterization study, THCB demonstrated notable binding affinity for CB1 receptors — greater than THCV but less than THC. The researchers found that THCB produced significant analgesic effects in the hot plate test and anti-inflammatory activity in the carrageenan-induced paw edema test in mice, suggesting therapeutic potential beyond its psychoactive properties. THCB's intermediate CB1 binding affinity suggests it may produce psychoactive effects that are milder than THC but potentially more consistent than THCV's dose-dependent switching behavior.
Despite these promising initial findings, THCB research has not progressed significantly since its discovery. Like many newly identified minor cannabinoids, THCB exists in very low concentrations in natural cannabis, making it difficult to study. The compound is occasionally found in commercial cannabinoid blends marketed for their novel psychoactive profiles, though product quality and accurate labeling remain concerns in the largely unregulated market.
Mechanism of Action
THCB binds to CB1 receptors with affinity comparable to THC, as demonstrated in the initial radioligand binding assays by Citti et al. Its four-carbon butyl side chain fits within the CB1 receptor binding pocket effectively, though not as deeply as THC's pentyl chain or THCP's heptyl chain. THCB also binds to CB2 receptors. In functional assays, THCB demonstrated analgesic activity (hot plate test) and anti-inflammatory effects (carrageenan-induced paw edema test), confirming in vivo biological activity consistent with cannabinoid receptor agonism. The specific interaction of THCB with non-cannabinoid targets (TRP channels, PPARs, serotonin receptors) has not been characterized.
Therapeutic Effects
Potential Benefits
Pain
Preclinical evidence. The 2019 discovery study by Citti et al. demonstrated significant analgesic effects in the hot plate test in mice, indicating THCB can reduce pain sensitivity through CB1 receptor-mediated mechanisms.
Inflammation
Preclinical evidence. The same 2019 study showed significant anti-inflammatory activity in the carrageenan-induced paw edema test in mice, comparable to other cannabinoid receptor agonists.
Side Effects & Risks
- ⚠Psychoactive effects expected based on CB1 binding affinity
- ⚠No human safety data available
- ⚠Side effect profile inferred from THC similarity
- ⚠Potential for impaired coordination and cognition
- ⚠May trigger positive drug tests for THC
Concentration & Sources
Typical Concentration
Trace amounts in natural cannabis; occasionally found in commercially produced cannabinoid blends; not widely available as an isolated product
Found In
Trace amounts in certain cannabis cultivars, first identified in the Italian medical variety FM2. Occasionally available in novelty cannabinoid blend products.
Legal Status
Not specifically scheduled in the US. Legal status uncertain — may be considered a THC analog under the Federal Analogue Act. Not addressed in most state or international laws.
Research Summary
THCB research is limited to the initial 2019 discovery and characterization study by Citti et al. published in Scientific Reports. This foundational paper confirmed THCB's natural occurrence, characterized its CB1 and CB2 binding affinity, and demonstrated in vivo analgesic and anti-inflammatory effects in mouse models. No subsequent studies have expanded on these findings. THCB occupies an interesting pharmacological position with its four-carbon side chain intermediate between THCV and THC, but whether this translates to unique therapeutic advantages remains to be determined through further research.
Related Cannabinoids
THCB FAQ
What is THCB?
THCB (tetrahydrocannabutol) is a naturally occurring cannabinoid discovered in 2019 by Italian researchers. It has a four-carbon (butyl) side chain, placing it between THCV (three-carbon chain) and THC (five-carbon chain) in the cannabinoid homolog series. THCB has demonstrated CB1 receptor binding affinity, analgesic effects, and anti-inflammatory effects in animal studies.
Does THCB get you high?
THCB is expected to produce psychoactive effects based on its CB1 receptor binding affinity, which is comparable to THC. However, no controlled human studies have evaluated THCB's subjective effects. Its four-carbon side chain suggests effects may be milder than THC but more consistent than THCV. Until human research is conducted, the specific quality and intensity of THCB's psychoactive effects remain uncertain.
How potent is THCB?
THCB's CB1 binding affinity is comparable to Delta-9 THC based on the initial 2019 radioligand binding assays, making it significantly less potent than THCP (which has 33x THC's affinity) but potentially more potent than Delta-8 THC or THCV. In animal models, THCB produced significant pain relief and anti-inflammatory effects, confirming meaningful biological potency. Human potency data is not available.
Is THCB legal?
THCB is not specifically scheduled in the United States or most other jurisdictions. However, its structural similarity to THC and psychoactive properties mean it could potentially be classified as a THC analog under the Federal Analogue Act. The legal status is uncertain and may vary by jurisdiction. As a naturally occurring cannabinoid, it may have a stronger legal argument than synthetic compounds like THC-O, but this has not been tested in courts.
Continue Exploring
Disclaimer: Cannabinoid information is provided for educational purposes only. Medical benefits are based on published research and are not intended as medical advice. Individual responses to cannabinoids vary. Always consult a healthcare professional before using cannabis for medical purposes. Legal status information is current as of publication but may change — verify your local laws.